IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes

Area of Science:

• Immunology
• Virology
• Respiratory Medicine

Background:

• Interferons (IFNs) are critical for pathogen defense by airway epithelial cells.
• Interferon-lambda (IFN-λ) levels may impact COVID-19 severity, but existing data are conflicting.
• Understanding serum IFN-λ dynamics is essential for COVID-19 patient management.

Purpose of the Study:

• To investigate serum IFN-λ levels over time in moderate and severe COVID-19.
• To correlate IFN-λ levels with cytokine production and clinical parameters.
• To elucidate the role of IFN-λ in COVID-19 pathogenesis and recovery.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) for serum IFN-λ quantification.
• Bio-Plex Pro Human Cytokine 17-plex Assay for cytokine profiling.
• Longitudinal analysis of 51 COVID-19 patients (moderate and severe).

Main Results:

• 68% of COVID-19 patients lacked detectable serum IFN-λ; deficiency correlated with severe disease.
• IFN-λ secretors with moderate COVID-19 maintained stable levels; severe cases showed a decline.
• Decreased IFN-λ correlated with inflammatory markers, while increased TNF-α and clinical improvement suggested a regulatory role in recovery.

Conclusions:

• Serum IFN-λ deficiency is a significant indicator of severe COVID-19.
• IFN-λ plays a vital, though not exclusive, role in antiviral response and COVID-19 recovery.
• IFN-λ influences disease progression but not overall survival.